Results 51 to 60 of about 3,283 (198)

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Ophthalmology and Therapy
Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or neovascular age ...
Scott M. Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, A. Mojebi, S. Keeping, Keith Chan, Theodore Leng, Nimesh A. Patel   +8 more
semanticscholar   +1 more source

Insights into the modulation of age‐related macular degeneration: Molecular and systems‐level perspectives

Acta Ophthalmologica, Volume 104, Issue S293, Page S4-S35, October 2026.
ENGLISH SUMMARY In developed countries, age‐related macular degeneration (AMD) is the leading cause of visual impairment in the aging population. Understanding of its pathogenesis is limited and the number of patients is predicted to continue rising. AMD is classified into two main forms: dry and neovascular AMD (dAMD and nAMD, respectively).
Hanna Heloterä
wiley   +1 more source

Inhibition of VEGF‐Induced Angiogenesis and Vascular Leakage by Bicistronic Co‐Expression of Aflibercept and COMP‐Ang1

Advanced Healthcare Materials, Volume 15, Issue 35, 18 September 2026.
A bicistronic rAAV8 vector encoding Aflibercept (Afb) and COMP‐cAng1 simultaneously coordinates VEGF clearance and Tie2‐mediated vessel maturation. In a 3D angiogenesis‐on‐a‐chip model, rAAV8‐Afb/cAng1 effectively reverses pathological barrier breakdown under clinical disease‐mimicking challenges.
Bong‐Kyu Kim, Jaehong Min, Sang‐Hee Park, Subeen Shin, Sangbin Yu, Jeong‐Eun Park, Sujin Kim, Wooju Park, Jihoon Ko, Sunjong Kwon   +9 more
wiley   +1 more source

Faricimab at 6 and 12 mg reduces pigment epithelium detachment in treatment-resistant macular neovascularization: an OCT and AI analysis

Scientific Reports
Macular neovascularization (MNV) in age-related macular degeneration (AMD) remains a therapeutic challenge, especially in eyes resistant to conventional anti-VEGF therapy.
Ines D. Nagel, Melanie D. Tran, Haochen Zhang, Lingyun Cheng, Anna Heinke, Nehal N. Mehta, Dirk-Uwe Bartsch, Fritz G. P. Kalaw, Mohamed Morsy, Arthur J. Mueller, William R. Freeman   +10 more
doaj   +1 more source

Faricimab in neovascular age-related macular degeneration: aqueous humor cytokine profiling and biomarker correlations. [PDF]

Front Med (Lausanne)
Purpose To investigate aqueous humor cytokine profile changes in neovascular age-related macular degeneration (nAMD) patients before and after intravitreal faricimab injection, and their correlation with ...
Wan Z, Chen X, Gao F, Shi F, Dai R, Peng Q, Wei Q.   +6 more
europepmc   +2 more sources

The impact of systemic long‐term medications for the development of age‐related macular degeneration

Acta Ophthalmologica, Volume 104, Issue 6, Page 674-681, September 2026.
Abstract Purpose Age‐related macular degeneration (AMD) is a leading cause of central vision loss in the elderly; however, the systemic factors that modulate its incidence and progression remain unclear. We sought to determine whether long‐term use of systemic medications, including diabetes and antithrombotic medications, corticosteroids and ...
Hanna Heloterä, Reijo Sund, Toni Rikkonen, Kai Kaarniranta   +3 more
wiley   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Efficacy and Safety of Faricimab for Macular Edema due to Retinal Vein Occlusion: 24-Week Results from the BALATON and COMINO Trials.

Ophthalmology (Rochester, Minn.)
PURPOSE To evaluate the 24-week efficacy and safety of the dual angiopoietin-2 (Ang-2)/vascular endothelial growth factor-A (VEGF-A) inhibitor, faricimab, compared with aflibercept in patients with macular edema due to retinal vein occlusion (RVO ...
R. Tadayoni, Liliana P. Paris, Carl J. Danzig, Francis Abreu, A. Khanani, C. Brittain, Timothy Y. Y. Lai, Z. Haskova, T. Sakamoto, A. Kotecha, P. Schlottmann, Ying Liu, A. Seres, Anne-Cecile Retiere, J. Willis, Young Hee Yoon   +15 more
semanticscholar   +1 more source

Current Landscape and Future Perspectives of Diabetic Retinopathy Therapy: Pharmacological Targets, Precision Laser Technology, and Clinical Evidence

MedComm, Volume 7, Issue 7, July 2026.
Targeted biological agents targeting VEGF, integrin, dopamine D2 receptor, ROCK, and BCL‐XL have entered the clinical trial phase and deserve particular attention. The treatment paradigm has shifted toward personalized and precision medicine, positioning optimized SML as a promising adjunctive therapy.
Xinying Hu, Zhe Cha, Ao Lu, Wuping Xu, Xiaoqing Zhang, Sheng Miao, Haiwei Xu, Xuedong Xu   +7 more
wiley   +1 more source

Early Outcomes After Initiation of Faricimab in Patients With Diabetic Macular Edema.

Ophthalmic Surgery Lasers and Imaging Retina
BACKGROUND AND OBJECTIVE This study evaluated treatment patterns and outcomes among patients with diabetic macular edema (DME) treated with the bispecific antibody faricimab in routine clinical practice in the United States.
Durga S. Borkar, D. Tabano, Ferhina S. Ali, Theodore Leng, Vincent Garmo, Ayesha Ahmed, Rachel Myers, Jacqueline K. Shaia, Giulio Barteselli, Rishi P. Singh   +9 more
semanticscholar   +1 more source